Pure Global
NCT06360133

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease
VivaVision Biotech, Inc·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Eye
Drug/Device/Intervention
VVN001 Ophthalmic Solution, 5%
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
VivaVision Biotech, Inc
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 3
Start date
Apr 01, 2024
End date
Mar 01, 2026
Enrollment
700 participants
Primary outcome

Corneal Fluorescein Staining

Summary

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed
 to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in
 Chinese subjects with dry eye disease.

ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06360133
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06360133 through Pure Global AI's free database. This Phase 3 trial is sponsored by VivaVision Biotech, Inc and is currently Not yet recruiting. The study focuses on Dry Eye. Target enrollment is 700 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.